London-based biotech startup Basecamp Research has raised $140 million in a funding round led by S32, with participation from Nvidia, Anthropic’s Anthology Fund, the NATO Innovation Fund, and Redalpine. Founded in 2020, the company develops biological AI models named EDEN to design antibiotics and cell therapy tools by training on genetic material gathered from unexplored natural environments such as oceans and rainforests.

The capital will be used to advance the company’s biological models and move its internal cell therapy candidates toward clinical trials. CTO Philip Lorenz emphasized that biology represents a vastly larger data and complexity challenge than natural language, noting that current public genomic databases are heavily biased toward a few species, such as humans, which limits an AI’s ability to learn broader biological mechanics.

While Basecamp has demonstrated early lab and mice data, the company has yet to prove its therapies are safe or effective in humans. The funding comes amid massive pharmaceutical investment into AI, even as industry-wide evidence of improved clinical trial success rates remains limited.

Why it matters

  • Validates investor interest in proprietary biological data collection over reliance on public, species-biased genomic databases.

  • Provides significant capital to scale specialized bio-AI models directly competing against traditional, small-dataset pharma approaches.

  • Offers strategic alignment opportunities for compute and model providers like Nvidia and Anthropic in life sciences.

Source: the-decoder.com